Core Insights - The Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking work in the field of peripheral immune tolerance, specifically the discovery of regulatory T cells (Treg) and the identification of the transcription factor Foxp3 as their "identity switch" [1] Group 1: Treg Cell Significance - Treg cells are unique "brake cells" in the immune system that specifically express CD4 molecules, functioning to precisely inhibit the overactivation of other immune cells, thereby preventing autoimmune diseases and regulating inflammatory responses [1] - Key proteins such as CTLA-4 and CCR8 are essential for Treg cells to perform their "immune brake" function, making them critical therapeutic targets in the biopharmaceutical field [1] Group 2: Innovation in Drug Development - Several innovative pharmaceutical companies are accelerating their development of Treg-related therapies, with companies like HBM focusing on the CTLA-4 target [2] - HBM's new generation antibody HBM4003 shows higher affinity for the CTLA-4 molecule, improved tumor tissue penetration, and significantly reduced systemic side effects, demonstrating promising safety and efficacy signals in clinical studies for various cancers [2] - HBM is also developing the HBM1022 antibody targeting CCR8, which effectively identifies and kills CCR8-positive Treg cells, positioning it as a potential breakthrough in tumor immunotherapy [2]
诺奖释放Treg细胞疗法潜力 和铂医药持续推进CTLA-4及CCR8抗体研发